Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Dhcs Medical Changes topic
No spam. Unsubscribe anytime.
Committee warns pharmacies about DHCS plan to flag prescriber NPIs and require ICD‑10 codes
Summary
The committee discussed DHCS notices that prescribers must enroll with a Type‑1 NPI before pharmacy claims are processed (flagging begins July 23, 2026) and that ICD‑10 codes will be required for adjudication in fall 2026. Members and public commenters warned these changes could cause prescription rejections and urged stakeholder outreach and education.
Staff updated the Communication & Public Education Committee that California’s Department of Health Care Services (DHCS) has published notices affecting pharmacy claims processing.
According to staff, DHCS’s Medical RX communications require prescribers who appear on pharmacy claims to be enrolled with a Type‑1 National Provider Identifier (NPI) and indicate that DHCS will begin flagging non‑enrolled NPIs on July 23, 2026. Separately, DHCS has announced that ICD‑10 diagnosis codes will be required for pharmacy claim adjudication beginning in fall 2026; that requirement will apply to claims submitted on or after the implementation date, including refills. Staff cautioned that if prescribers are not registered or do not provide required diagnosis codes, pharmacies could see rejections that delay patient access.
Members and public commenters raised operational concerns. Committee members said the practical burden will fall on pharmacists and pharmacies to resolve claim rejections even though prescribers must enroll. Commenters reported thousands of providers are not yet enrolled and noted enrollment can take months. Public commenters recommended immediate outreach to pharmacy schools, professional organizations and prescriber groups, and urged DHCS to provide clearer outreach and timelines. One member flagged privacy concerns about very specific diagnosis codes that may reveal sensitive information (for example, codes that could disclose gender‑affirming care or sexual behavior), and asked staff to consider confidentiality risks when encouraging ICD‑10 use.
Staff and members suggested steps the board could take, including a public alert on the board website, routine communications to pharmacists, coordination with Department of Consumer Affairs and DHCS, and outreach to pharmacy schools so that new graduates learn the new requirements.
No formal board action was taken; members directed staff to continue outreach and to report back on further DHCS guidance.
